{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:45:45Z","timestamp":1793148345499,"version":"4.5.0"},"reference-count":25,"publisher":"American Association for Cancer Research (AACR)","issue":"2","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["2P01CA049605\u201329A1"],"award-info":[{"award-number":["2P01CA049605\u201329A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA248968"],"award-info":[{"award-number":["K08CA248968"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Immune effector cell\u2013associated hemophagocytic lymphohistiocytosis\u2013like syndrome (IEC-HS) is a poorly characterized inflammatory toxicity of chimeric antigen receptor (CAR) T cells with high risk of mortality. In this study, we describe IEC-HS manifestations in patients with large B-cell lymphoma and B-cell acute lymphoblastic leukemia after CD22-directed CAR T cells. IEC-HS occurred in 19 of 54 patients (35%), including 11 grade 1 and 8 grade 2 or higher. IEC-HS was associated with higher nonrelapse mortality (NRM) yet lower relapse rates. CAR T-cell expansion in peripheral blood was significantly associated with IEC-HS severity. Cytokine profiling identified 41 cytokines primarily related to the IFN\u03b3, TNF\u03b1, and IL1 families that significantly correlated with IEC-HS severity. We developed a parsimonious model composed of IFN\u03b3, IL10, and IL1RA that correlated with grade 2+ IEC-HS on day 14, outperforming the full signature (AUC 0.93 vs. 0.75, P = 0.038). Thus, a cytokine signature with potential prognostic utility helps distinguish IEC-HS from inflammatory toxicities with overlapping symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>IEC-HS is a serious inflammatory toxicity of CAR T cells. We demonstrate that IEC-HS after CD22-directed CAR T-cell therapy is associated with lower rates of relapse yet higher NRM. CAR T-cell expansion and a 41-cytokine signature are associated with IEC-HS, and a simplified signature of IFN\u03b3, IL10, and IL1RA precedes severe disease.<\/jats:p>\n                    <jats:p>See related commentary by Rocco and Shah, p. 163<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0262","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:57:06Z","timestamp":1766091426000},"page":"225-233","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical and Cytokine Features of Immune Effector Cell\u2013Associated Hemophagocytic Lymphohistiocytosis\u2013Like Syndrome"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9786-3010","authenticated-orcid":false,"given":"Hrishikesh K.","family":"Srinagesh","sequence":"first","affiliation":[{"name":"1Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5239-7343","authenticated-orcid":false,"given":"Anne Marijn","family":"Kramer","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-6546","authenticated-orcid":false,"given":"John H.","family":"Baird","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California."},{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope National Medical Center 2 Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, , Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0861-1362","authenticated-orcid":false,"given":"Agnes","family":"Reschke","sequence":"additional","affiliation":[{"name":"3Division of Pediatric Hematology\/Oncology\/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California."},{"id":[{"id":"https:\/\/ror.org\/01hcyya48","id-type":"ROR","asserted-by":"publisher"}],"name":"Cincinnati Children\u2019s Hospital 4 Divisions of Critical Care and Oncology, , Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4157-3863","authenticated-orcid":false,"given":"Bita","family":"Sahaf","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00f54p054","id-type":"ROR","asserted-by":"publisher"}],"name":"Stanford University 5 Center for Cancer Cell Therapy, Stanford Cancer Institute, , Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2969-4571","authenticated-orcid":false,"given":"Juancarlos","family":"Cancilla","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00f54p054","id-type":"ROR","asserted-by":"publisher"}],"name":"Stanford University 5 Center for Cancer Cell Therapy, Stanford Cancer Institute, , Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6992-8815","authenticated-orcid":false,"given":"Shriya","family":"Syal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00f54p054","id-type":"ROR","asserted-by":"publisher"}],"name":"Stanford University 5 Center for Cancer Cell Therapy, Stanford Cancer Institute, , Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8372-1166","authenticated-orcid":false,"given":"Yi-Jiun","family":"Su","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California."},{"name":"6Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3792-6750","authenticated-orcid":false,"given":"Neha","family":"Agarwal","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6337-9079","authenticated-orcid":false,"given":"Alexandria M.","family":"Jensen","sequence":"additional","affiliation":[{"name":"7Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-7597","authenticated-orcid":false,"given":"Liora M.","family":"Schultz","sequence":"additional","affiliation":[{"name":"3Division of Pediatric Hematology\/Oncology\/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-4434","authenticated-orcid":false,"given":"Nikeshan","family":"Jeyakumar","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7445-3190","authenticated-orcid":false,"given":"Sneha","family":"Ramakrishna","sequence":"additional","affiliation":[{"name":"3Division of Pediatric Hematology\/Oncology\/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7182-2592","authenticated-orcid":false,"given":"Kara L.","family":"Davis","sequence":"additional","affiliation":[{"name":"3Division of Pediatric Hematology\/Oncology\/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-1796","authenticated-orcid":false,"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-3860","authenticated-orcid":false,"given":"Steven A.","family":"Feldman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00f54p054","id-type":"ROR","asserted-by":"publisher"}],"name":"Stanford University 5 Center for Cancer Cell Therapy, Stanford Cancer Institute, , Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-9023","authenticated-orcid":false,"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[{"name":"3Division of Pediatric Hematology\/Oncology\/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California."},{"id":[{"id":"https:\/\/ror.org\/00f54p054","id-type":"ROR","asserted-by":"publisher"}],"name":"Stanford University 5 Center for Cancer Cell Therapy, Stanford Cancer Institute, , Stanford, California."},{"name":"8Parker Institute for Cancer Immunotherapy, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori S.","family":"Muffly","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California."},{"id":[{"id":"https:\/\/ror.org\/00f54p054","id-type":"ROR","asserted-by":"publisher"}],"name":"Stanford University 5 Center for Cancer Cell Therapy, Stanford Cancer Institute, , Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-3354","authenticated-orcid":false,"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2026030403072690600_bib1","first-page":"438.e1","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"2026030403072690600_bib2","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"2026030403072690600_bib3","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv"},{"key":"2026030403072690600_bib4","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"2026030403072690600_bib5","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"key":"2026030403072690600_bib6","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1172\/JCI130059","article-title":"Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients","volume":"130","author":"Ishii","year":"2020","journal-title":"J Clin Invest"},{"key":"2026030403072690600_bib7","doi-asserted-by":"crossref","first-page":"6134","DOI":"10.1182\/bloodadvances.2023010708","article-title":"Free interleukin-18 is elevated in CD22 CAR T-cell\u2013associated hemophagocytic lymphohistiocytosis\u2013like toxicities","volume":"7","author":"Rocco","year":"2023","journal-title":"Blood Adv"},{"key":"2026030403072690600_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"2026030403072690600_bib9","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026030403072690600_bib10","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41375-024-02220-y","article-title":"CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results","volume":"38","author":"Schultz","year":"2024","journal-title":"Leukemia"},{"key":"2026030403072690600_bib11","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood.2020009432","article-title":"CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma","volume":"137","author":"Baird","year":"2021","journal-title":"Blood"},{"key":"2026030403072690600_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","article-title":"CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study","volume":"404","author":"Frank","year":"2024","journal-title":"Lancet"},{"key":"2026030403072690600_bib13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1158\/2159-8290.CD-24-1071","article-title":"Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with relapsed\/refractory LBCL","volume":"15","author":"Su","year":"2025","journal-title":"Cancer Discov"},{"key":"2026030403072690600_bib14","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"2026030403072690600_bib15","doi-asserted-by":"crossref","first-page":"e0251216","DOI":"10.1371\/journal.pone.0251216","article-title":"Coagulation disorders in patients with severe hemophagocytic lymphohistiocytosis","volume":"16","author":"Valade","year":"2021","journal-title":"PLoS One"},{"key":"2026030403072690600_bib16","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1158\/1078-0432.CCR-22-0822","article-title":"Comprehensive serum proteome profiling of cytokine release syndrome and immune effector cell\u2013associated neurotoxicity syndrome patients with B-cell ALL receiving CAR T19","volume":"28","author":"Diorio","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026030403072690600_bib17","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.4049\/jimmunol.150.10.4687","article-title":"Induction of circulating IL-1 receptor antagonist by IFN treatment","volume":"150","author":"Tilg","year":"1993","journal-title":"J Immunol"},{"key":"2026030403072690600_bib18","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome\u2013like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J Clin Invest"},{"key":"2026030403072690600_bib19","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1182\/bloodadvances.2019000898","article-title":"Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1\/2 inhibitor ruxolitinib","volume":"3","author":"Goldsmith","year":"2019","journal-title":"Blood Adv"},{"key":"2026030403072690600_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jaci.2022.07.026","article-title":"Combined IFN-\u03b3 and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice","volume":"151","author":"Joly","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026030403072690600_bib21","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"key":"2026030403072690600_bib22","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood.2024026586","article-title":"Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study","volume":"146","author":"Frigault","year":"2025","journal-title":"Blood"},{"key":"2026030403072690600_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026030403072690600_bib24","article-title":"PLS: partial least squares projections to latent structures","volume-title":"3D QSAR in drug design, theory, methods, and applications","author":"Wold","year":"1993"},{"key":"2026030403072690600_bib25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0262\/3717215\/bcd-25-0262.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0262\/3732814\/bcd-25-0262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/2\/225\/3740446\/bcd-25-0262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/2\/225\/3740446\/bcd-25-0262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:07:37Z","timestamp":1772611657000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/2\/225\/774788\/Clinical-and-Cytokine-Features-of-Immune-Effector"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,12,18]]},"published-print":{"date-parts":[[2026,3,4]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0262","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.31484332","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484287","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484320","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484299","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484314","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484269","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484302","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484338","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484308","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484281","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484293","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484353","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484278","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484323","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484311","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484347","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484335","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484329","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484317","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484290","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484272","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484284","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484341","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8335729","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}